Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2221PDF: 1756HTML: 820 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2961PDF: 1397HTML: 3719Untitled: 205Untitled: 218Untitled: 193 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
840PDF: 115HTML: 190 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
534PDF: 267HTML: 104 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1308PDF: 1095HTML: 239 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1097PDF: 1199Suppl. Files: 580HTML: 94 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1437HTML: 623PDF: 857 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3876PDF: 1702HTML: 11773Figures Haase: 223 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3414PDF: 2004HTML: 7567 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2039PDF: 748HTML: 716Table1: patient's characteristics: 165Table 2: profile of each patient: 189 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2520HTML: 293PDF: 923 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3614PDF: 1253HTML: 5088Incidence age-standardized rates for HL across the Mediterranean basin: 224 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3323PDF: 1735HTML: 1149 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2637PDF: 821HTML: 5357 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9235PDF: 6147HTML: 88018Fig.1b: 202Fig.1c: 210Fig.2a: 198Fig.2b: 193Fig.4: 212Fig.2c: 197Fig.3: 199Tab.1: 250Tab.2: 224Tab.3: 209Tab.4: 244Fig1a: 204 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1621PDF: 1071HTML: 412 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3653PDF: 2565HTML: 1545 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3726PDF: 919HTML: 6857 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2822PDF: 1045HTML: 248Suppl. Files: 526 -
SOLITARY PLASMACYTOMA
4003PDF: 2230HTML: 1345fIGURES 1,2: 238 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2235PDF: 1643HTML: 376 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3120PDF: 894HTML: 7289Kost Fig1: 204Kost Fig 2: 192Kost Fig3: 195Kost Fig 4: 207Kost Fig5: 206Kost fig 6: 191 -
-
TYROSINE KINASE INHIBITORS AND PREGNANCY
3707PDF: 1698HTML: 2687 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4081PDF: 1565HTML: 9238Untitled: 289Untitled: 197Untitled: 182Untitled: 175Untitled: 198Untitled: 354 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2528PDF: 806HTML: 1743 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2830PDF: 1155HTML: 3303 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4044PDF: 1073HTML: 3887Untitled: 183Cneo. Fig.1: 119Untitled: 113Untitled: 140Untitled: 146 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2881PDF: 1039HTML: 5630 -







